Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Murphy, MO
Audie Murphy, Independence, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20120175870 | FLUSH VALVE PIPE STABILIZER - A bracket assembly for stabilizing the connection between a pair of joined pipe segments includes a bracket element attached to each pipe segment, and a yoke element connecting the brackets and reinforcing the connection between the pipe segments. The pipe segments may be in a linear arrangement or may have an angular arrangement. The bracket may be a collar, a split ring, or a pair of joined arcuate pieces. The yoke element may be straight or curved. | 07-12-2012 |
Clifton N. Murphy, Columbia, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20110213198 | HIGH-THROUGHPUT AND NON-INVASIVE METHOD TO VITRIFY PORCINE EMBRYOS - The present invention provides a practical, non-invasive, and efficient method for cryopreservation of an in-vitro-produced porcine embryo. The inventive method treats the NP (such as IVF- or NT-derived) embryo at the one-cell or cleavage stage prior to compaction with high osmolality followed by high speed centrifugation. The high osmolality treatment enlarges the periviteline space, and with centrifugation, enables the separation of the lipids from the cytoplasm. The lipid-separated embryos after high osmolality treatment have been successfully cryopreserved and later recovered and transferred to produce live offspring. | 09-01-2011 |
Forrest Murphy, St. Louis, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20100131969 | Methods and apparatus for audience research in a content-based network - Methods and apparatus for accurate, secure and uniform exchange of audience research data. In one embodiment, viewership data is provided in real-time and offers the ability to monitor audience activities regarding, among others, broadcast, VOD or DVR content. A standardized message configuration is optionally used also to permit maximum uniformity and accessibility of the data. Accuracy of data exchange is enforced by implementing a method of detecting system failures, and the transmission of incomplete messages. Subscriber privacy and anonymity is also maintained via e.g., hashing or encrypting data relating to the CPE and/or subscriber, thus ensuring that stored data is not traceable to a specific user account. The methods and apparatus may also be utilized in conjunction with systems enabling the insertion and/or recommendation of content or advertising based on data collected regarding user actions or events. Business methods are also disclosed. | 05-27-2010 |
Forrest M. Murphy, Clayton, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20090204615 | PERSISTENT CROSS PLATFORM COLLECTION OF AUDIENCE DATA - Previous attempts to measure content and/or advertising consumption treat each category as a unique silo of information. A method, system, and method of doing business generate a profile by obtaining at least a first and second data measurement from a user impression of a linear source of content and a user impression of a time-shifted source of content and/or a user impression of an interactive source of content, and associating the measurements with a user ID to generate a profile. | 08-13-2009 |
Kenneth Murphy, St. Louis, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20120214972 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided. | 08-23-2012 |
| 20120232259 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided. | 09-13-2012 |
Kenneth M. Murphy, St. Louis, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20080269464 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided. | 10-30-2008 |
| 20100166784 | METHOD AND COMPOSITIONS FOR MODULATING TH17 CELL DEVELOPMENT - The invention encompasses methods and compositions for modulating Th17 development. | 07-01-2010 |
| 20100310582 | METHODS FOR INDUCING IN VIVO TOLERANCE - The present invention encompasses methods for inducing in vivo tolerance to a foreign tissue. | 12-09-2010 |
| 20110230647 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided. | 09-22-2011 |
| 20110236401 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The invention derives from the identification of HVEM as the native ligand for BTLA. The invention provides compositions and methods for modulating BTLA-HVEM interactions and BTLA and HVEM activity, which are useful for modulating immune responses. Agonists and antagonists of the BTLA-HVEM interaction are provided, and methods of treating a variety of conditions through the modulation of immune responses are provided. | 09-29-2011 |
| 20120207759 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided. | 08-16-2012 |
| 20120322986 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided. | 12-20-2012 |
Kevin Patrick Murphy, Palmyra, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20120127321 | WALL PLATE DIGITAL TELEVISION ANTENNA SIGNAL METER AND METHOD - A wall plate assembly having a television channel select switch, a channel display, and a signal strength display. A circuit board on the rear of the wall plate includes a television antenna connector, a television output connector, and control electronics. The control electronics displays the selected channel in the channel display, determines the signal strength for the selected channel in any signal on the television antenna connector and displays it in the signal strength display. The control electronics delivers the signal for the selected channel to the television output connector. | 05-24-2012 |
M. Keith Murphy, Clayton, MO US
Sharon E. Murphy, Ballwin, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20120173437 | SYSTEMS ENGINEERING PROCESS - A method and system for implementing a project for a customer. A computer readable Requirements Traceability and Verification Matrix (RTVM). The RTVM is stored in a computer readable storage device. A verification is implemented, which verifies: an acceptability of business requirements of the project due to business requirements review (BRR) exit criteria having been satisfied, an acceptability of system requirements of the project due to system requirements review (SRR) exit criteria having been satisfied, an acceptability of component requirements of the project due to component requirements review (PDR) exit criteria having been satisfied. The business requirements are decomposed into the system requirements. The system requirements are decomposed into the component requirements. In response to the verification, the RVTM is updated with verification information relating to the business requirements, verification information relating to the system requirements, and verification information relating to the component requirements. | 07-05-2012 |
Sharon E. Murphy, Hazelwood, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20100004966 | SYSTEMS ENGINEERING PROCESS - A method for implementing a project for a customer. Business requirements are developed for the project and are reviewed for acceptability in accordance with Business Requirements Review (BRR) exit criteria. System requirements are developed for the project and are reviewed for acceptability in accordance with system requirements review (SRR) exit criteria. Component requirements are developed for the project and are reviewed for acceptability in accordance with Preliminary Design Review (PDR) exit criteria. The business requirements are decomposed into the system requirements. The system requirements are decomposed into the component requirements. A Requirements Traceability and Verification Matrix (RTVM) is generated when the business requirements are established. The RTVM is updated throughout the life of the project. The RTVM includes verification information relating to the business requirements, the system requirements, and the component requirements. The RTVM depicts hierarchical relationships between the business requirements, the system requirements, and the component requirements. | 01-07-2010 |
Theresa Murphy, St. Louis, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20080269464 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided. | 10-30-2008 |
| 20100166784 | METHOD AND COMPOSITIONS FOR MODULATING TH17 CELL DEVELOPMENT - The invention encompasses methods and compositions for modulating Th17 development. | 07-01-2010 |
| 20120214972 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided. | 08-23-2012 |
| 20120232259 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided. | 09-13-2012 |
Theresa L. Murphy, St. Louis, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20110230647 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided. | 09-22-2011 |
| 20110236401 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The invention derives from the identification of HVEM as the native ligand for BTLA. The invention provides compositions and methods for modulating BTLA-HVEM interactions and BTLA and HVEM activity, which are useful for modulating immune responses. Agonists and antagonists of the BTLA-HVEM interaction are provided, and methods of treating a variety of conditions through the modulation of immune responses are provided. | 09-29-2011 |
| 20120207759 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided. | 08-16-2012 |
| 20120322986 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided. | 12-20-2012 |